OBJECTIVES To analyse the association between refill adherence to lipid-lowering medications, and the risk of cardiovascular disease (CVD) and mortality in patients with type 2 diabetes mellitus. DESIGN Cohort study. SETTING National population-based cohort of Swedish patients with type 2 diabetes mellitus. PARTICIPANTS 86 568 patients aged ≥18 years, registered with type 2 diabetes melli...

BACKGROUND It has been hypothesised that health conscious individuals tend to take better care of themselves by greater adherence to preventive medications. We examined, whether long-term changes in dietary habits and physical activity were associated with initiation of lipid-lowering and antihypertensive medications. METHODS The study population consisted of two subsamples from the populatio...

BACKGROUND Lipid-reduction pharmacotherapy is often employed to reduce morbidity and mortality risk for patients with dyslipidemia or established cardiovascular disease. Associations between socioeconomic factors and the prescribing and use of lipid-lowering agents have been reported in several developed countries. METHODS We evaluated the association of census tract-level neighborhood househ...

In the last 2 decades, in-hospital mortality for acute coronary syndromes and percutaneous and surgical revascularization has decreased markedly. To continue to make progress and to meet the goal set by the American Heart Association (AHA) of reducing coronary heart disease (CHD) and stroke by 25% by 2010,1 the focus of treatment in patients hospitalized with CHD must evolve from treating sympt...

BACKGROUND Nonstatin lipid-lowering therapy is adjunctive therapy for high-risk individuals on statins or monotherapy among those who cannot tolerate statins. OBJECTIVES This study determined time trends between 2007 and 2011 for statin and nonstatin lipid-lowering therapy (niacin, fibrates, bile acid sequestrants, and ezetimibe) use among Medicare beneficiaries with coronary heart disease (C...